Frontiers in adjuvant therapy in stage II-III melanoma

被引：0
|
作者：
Eggermont, AMM [1 ]
机构：
[1] Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Dept Surg Oncol, NL-3075 EA Rotterdam, Netherlands
来源：
TUMORI JOURNAL | 2001年 / 87卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S60 / S63
页数：4
相关论文
共 50 条
  • [31] Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer
    Yuanyuan Chen
    Mingyue Xu
    Qianwen Ye
    Jia Xiang
    Tianhui Xue
    Tao Yang
    Long Liu
    Bing Yan
    BMC Cancer, 22
  • [32] Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer
    Chen, Yuanyuan
    Xu, Mingyue
    Ye, Qianwen
    Xiang, Jia
    Xue, Tianhui
    Yang, Tao
    Liu, Long
    Yan, Bing
    BMC CANCER, 2022, 22 (01)
  • [33] Glycemic Variability in Patients With Stage II-III Colon Cancer Treated With Surgery and Adjuvant Chemotherapy
    Mandolfo, Natalie Rasmussen
    Berger, Ann M.
    Struwe, Leeza A.
    Shade, Marcia Y.
    Goldner, Whitney
    Klute, Kelsey
    Langenfeld, Sean J.
    Hammer, Marilyn J.
    ONCOLOGY NURSING FORUM, 2022, 49 (06) : 571 - 584
  • [34] Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma
    Gartrell, Robyn D.
    Marks, Douglas K.
    Rizk, Emanuelle M.
    Bogardus, Margaret
    Gerard, Camille L.
    Barker, Luke W.
    Fu, Yichun
    Esancy, Camden L.
    Li, Gen
    Ji, Jiayi
    Rui, Shumin
    Ernstoff, Marc S.
    Taback, Bret
    Pabla, Sarabjot
    Chang, Rui
    Lee, Sandra J.
    Krolewski, John J.
    Morrison, Carl
    Horst, Basil A.
    Saenger, Yvonne M.
    CLINICAL CANCER RESEARCH, 2019, 25 (08) : 2494 - 2502
  • [35] Impact of Rurality on Time to Therapy and Survival for Stage II-III Esophageal Adenocarcinoma
    Kusema, Escar T.
    Even, Zachary
    Sticca, Robert P.
    Ganai, Sabha
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2024, 239 (05) : S262 - S262
  • [36] Adjuvant interferon for stage II melanoma
    Haluska, FG
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) : 3205 - 3206
  • [37] Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era
    Straker, Richard J., III
    Song, Yun
    Sun, James
    Shannon, Adrienne B.
    Cohen, Leah S.
    Muradova, Elnara
    Daou, Hala
    Krause, Kate
    Li, Siming
    Frederick, Dennie T.
    Rhodin, Kristen E.
    Brizel, David M.
    Boland, Genevieve M.
    Beasley, Georgia M.
    Wuthrick, Evan J.
    Sondak, Vernon K.
    Zager, Jonathan S.
    Lin, Alexander
    Lukens, John N.
    Karakousis, Giorgos C.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (07) : 3512 - 3521
  • [38] Adjuvant therapy in stage IIIA melanoma
    Eggermont, Alexander M. M.
    Suciu, Stefan
    Robert, Caroline
    LANCET ONCOLOGY, 2021, 22 (07): : E300 - E300
  • [39] A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma
    Taylor, A. M.
    Galea, C.
    Varey, A. H. R.
    Shannon, K. F.
    Ch'ng, S.
    Saw, R. P. M.
    Pennington, T. E.
    Stretch, J.
    Spillane, A. J.
    van Akkooi, A. C. J.
    da Silva, I. Pires
    Carlino, M. S.
    Scolyer, R. A.
    Long, G. V.
    Lo, S. N.
    Menzies, A. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S939 - S939
  • [40] Adjuvant and Neoadjuvant Therapy in High-Risk Stage III Cutaneous Melanoma
    Sondak, Vernon K.
    Khushalani, Nikhil I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 16 - 17
12345